426 related articles for article (PubMed ID: 33682547)
21. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis.
Li S; Xu C; Hu S; Lai J
Eur Psychiatry; 2024 Mar; 67(1):e29. PubMed ID: 38487836
[TBL] [Abstract][Full Text] [Related]
22. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.
Bergeson JG; Kalsekar I; Jing Y; You M; Forbes RA; Hebden T
Am Health Drug Benefits; 2012 Sep; 5(6):379-86. PubMed ID: 24991334
[TBL] [Abstract][Full Text] [Related]
23. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H
Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804
[TBL] [Abstract][Full Text] [Related]
24. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine.
Huang H; Schmerold L; Dembek C; Fan Q; Dieyi C; Williams GR; Loebel A
J Med Econ; 2021; 24(1):352-362. PubMed ID: 33588674
[TBL] [Abstract][Full Text] [Related]
25. Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.
Nair SS; Chua CJM; Teo DCL
East Asian Arch Psychiatry; 2021 Sep; 31(3):81-83. PubMed ID: 34588318
[TBL] [Abstract][Full Text] [Related]
26. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
27. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
28. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
29. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.
Gianfrancesco F; Rajagopalan K; Goldberg JF; Wang RH
Bipolar Disord; 2007 May; 9(3):252-61. PubMed ID: 17430300
[TBL] [Abstract][Full Text] [Related]
30. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
J Clin Psychiatry; 2006 Feb; 67(2):222-32. PubMed ID: 16566617
[TBL] [Abstract][Full Text] [Related]
31. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.
Yan T; Greene M; Chang E; Houle CR; Tarbox MH; Broder MS
Clinicoecon Outcomes Res; 2020; 12():81-89. PubMed ID: 32104020
[TBL] [Abstract][Full Text] [Related]
32. Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study.
Pae CU; Nassir Ghaemi S; Patkar A; Chae JH; Bahk WM; Jun TY; Masand P
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1322-5. PubMed ID: 16631294
[TBL] [Abstract][Full Text] [Related]
33. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
34. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
35. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Yoshimura R; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Dec; 40(4):417-422. PubMed ID: 32902200
[TBL] [Abstract][Full Text] [Related]
36. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J
J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179
[TBL] [Abstract][Full Text] [Related]
37. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
38. Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.
Ryan PB; Schuemie MJ; Ramcharran D; Stang PE
Drugs Aging; 2017 Mar; 34(3):211-219. PubMed ID: 28124262
[TBL] [Abstract][Full Text] [Related]
39. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
40. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
